Business Wire

Avanci Launches 5G Connected Vehicle Licensing Program

16.8.2023 14:00:00 EEST | Business Wire | Press release

Share

Avanci, the independent global leader in joint licensing solutions, today announced the launch of its 5G Connected Vehicle program that will simplify the licensing of the cellular technologies used in next generation connected vehicles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230816648734/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Avanci 5G Vehicle launches to simplify licensing of cellular technologies for next generation connected vehicles. (Graphic: Avanci)

Kasim Alfalahi, founder and Chief Executive Officer of Avanci, said: “Avanci was created with a vision of transforming how technology is shared. We ensure that the work of thousands of inventors around the world is recognized and rewarded. At the same time, by simplifying technology access, we enable companies to build exciting new products that are improving the lives of people across the globe, every day.”

The Avanci 5G Vehicle program covers patented technologies essential for 5G, 4G, 3G and 2G connectivity, including cellular vehicle-to-everything (C-V2X) which enables vehicles to directly communicate with other vehicles, cyclists, pedestrians, and transportation infrastructure.

Laurie Fitzgerald, Senior Vice President at Avanci, said: “The launch of our 5G Connected Vehicle program is an important milestone for Avanci, as we can now provide automakers with the efficient option of a single agreement, covering patented cellular technologies from dozens of organizations worldwide, to support the roll-out of 5G in connected vehicles. We appreciate the confidence and trust of all the partners who worked with us to create this new program and we are proud to make it a reality.”

This new Avanci program builds on the success of Avanci 4G Vehicle, which today has more than 130 million connected vehicles on the world’s roads from more than 80 automotive brands covered by an Avanci 4G Vehicle license.

Roger Lanctot, Director, Automotive Connected Mobility at TechInsights said, “The transition from 4G technology to 5G will be unlike any prior wireless changeover. For the first time, automakers are facing an industry transformation touching all aspects of vehicle development and sales, and car ownership. With 25 global automakers committed to deployment, prospects are bright for 5G to transform vehicle connectivity. TechInsights forecasts that the share of 5G connected vehicles will grow to over 50% of new vehicle production in 5 years’ time.”

Avanci launches this new program with a license that covers thousands of patented technologies essential for implementing cellular connectivity. Details of the Avanci 5G Vehicle program, including the 59 initial participants, together with terms including early adopter pricing for licensees, can be found at avanci.com/5Gvehicle.

About Avanci

Avanci believes that sharing patented technology can be simpler. An independent intermediary not owned or controlled by licensors or licensees, Avanci works at the intersection of different industries. Our one-stop solutions are designed to bring efficiency, convenience, and predictability to the licensing process. Since 2016, Avanci has been driving innovation forward by making connections through our licensing platforms. Avanci is proud to be a part of the World Economic Forum’s Global Innovators Community.
www.avanci.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Avanci
Mark Durrant
Vice President, Marketing & Communications
media@avanci.com
+1 (469) 480-2558 / +44 7875 276867

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye